Cellebrite DI Ltd. $CLBT Shares Acquired by Quantbot Technologies LP

Quantbot Technologies LP grew its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 57.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 223,832 shares of the company’s stock after purchasing an additional 81,749 shares during the quarter. Quantbot Technologies LP’s holdings in Cellebrite DI were worth $3,581,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in CLBT. Natixis Advisors LLC purchased a new position in Cellebrite DI in the 1st quarter valued at approximately $469,000. US Bancorp DE acquired a new stake in shares of Cellebrite DI in the first quarter valued at $308,000. Swiss National Bank boosted its holdings in Cellebrite DI by 27.0% in the first quarter. Swiss National Bank now owns 191,300 shares of the company’s stock valued at $3,717,000 after purchasing an additional 40,700 shares during the period. Invesco Ltd. grew its stake in Cellebrite DI by 122.1% during the 1st quarter. Invesco Ltd. now owns 3,296,079 shares of the company’s stock worth $64,043,000 after purchasing an additional 1,811,757 shares in the last quarter. Finally, Polen Capital Management LLC increased its holdings in Cellebrite DI by 47.1% during the 1st quarter. Polen Capital Management LLC now owns 14,849 shares of the company’s stock worth $289,000 after purchasing an additional 4,754 shares during the period. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CLBT has been the subject of several recent research reports. Lake Street Capital lifted their price objective on Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Needham & Company LLC lifted their price target on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday. JPMorgan Chase & Co. increased their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Finally, Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.00.

Cellebrite DI Stock Up 1.1%

Shares of Cellebrite DI stock opened at $18.20 on Friday. Cellebrite DI Ltd. has a 52 week low of $13.10 and a 52 week high of $26.30. The firm’s 50 day moving average is $17.78 and its two-hundred day moving average is $16.52. The firm has a market capitalization of $4.36 billion, a P/E ratio of 58.71, a P/E/G ratio of 3.07 and a beta of 1.29.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.05). The company had revenue of $126.03 million for the quarter, compared to analysts’ expectations of $122.98 million. Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The firm’s quarterly revenue was up 17.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.14 EPS. As a group, research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.